The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma
Abstract Background There are limited reports on nanoparticle albumin bound‐paclitaxel (nab‐paclitaxel) regimens as second‐ or third‐line treatments for advanced esophageal squamous cell carcinoma (ESCC). Additionally, its safety and efficacy in ESCC patients after failure of first‐line programmed c...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14885 |
| _version_ | 1797820063423660032 |
|---|---|
| author | Dao Xin Yan Song Lan Mu Bo Zhang Ling Qi Jing Gao Xingyuan Wang Jianping Xu Tao Qu Jing Huang |
| author_facet | Dao Xin Yan Song Lan Mu Bo Zhang Ling Qi Jing Gao Xingyuan Wang Jianping Xu Tao Qu Jing Huang |
| author_sort | Dao Xin |
| collection | DOAJ |
| description | Abstract Background There are limited reports on nanoparticle albumin bound‐paclitaxel (nab‐paclitaxel) regimens as second‐ or third‐line treatments for advanced esophageal squamous cell carcinoma (ESCC). Additionally, its safety and efficacy in ESCC patients after failure of first‐line programmed cell death protein‐1 (PD‐1) blockade plus chemotherapy have not been reported. In this study, we aimed to assess the efficacy and tolerability of nab‐paclitaxel regimens as second‐ or later‐line treatment in advanced ESCC. Methods We retrospectively reviewed clinical data of advanced ESCC patients who participated in a randomized phase III clinical study and received serplulimab or placebo plus chemotherapy at our institution, and consecutive patients who received subsequent nab‐paclitaxel‐based regimens as second‐ or later‐line treatment were included for data collection and analysis. Results A total of 39 patients were included, 25 (64.1%) received serplulimab plus chemotherapy and 14 (35.9%) received chemotherapy alone as first‐line treatment. Treatment strategies included nab‐paclitaxel monotherapy (7/39, 17.9%), or in combination with other chemotherapy (19/39, 48.7%), with anti‐PD‐1 antibodies (12/39, 30.8%) or with nimotuzumab (1/39, 2.6%). Overall, the objective response rate (ORR) and disease control rate (DCR) were 33.3% (13/39) and 61.5% (24/39), respectively. With a median follow‐up of 9.7 months, the median progression‐free survival and median overall survival were 5.0 and 7.9 months, respectively. The most common adverse events were neuropathy peripheral (30.8%), anemia (30.8%), neutrophil count decreased (23.1%), and nausea (20.5%). Conclusions Nab‐paclitaxel‐based regimen could be a safe and effective option as second‐ or later‐line treatment in patients with advanced ESCC, regardless of their previous exposure to PD‐1 inhibitors. |
| first_indexed | 2024-03-13T09:31:55Z |
| format | Article |
| id | doaj.art-f70e0018fafb4473bafc61042dd1b37d |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-03-13T09:31:55Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-f70e0018fafb4473bafc61042dd1b37d2023-05-25T23:42:36ZengWileyThoracic Cancer1759-77061759-77142023-05-0114151392139710.1111/1759-7714.14885The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinomaDao Xin0Yan Song1Lan Mu2Bo Zhang3Ling Qi4Jing Gao5Xingyuan Wang6Jianping Xu7Tao Qu8Jing Huang9Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Oncology Guizhou Provincial People's Hospital Guiyang ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaAbstract Background There are limited reports on nanoparticle albumin bound‐paclitaxel (nab‐paclitaxel) regimens as second‐ or third‐line treatments for advanced esophageal squamous cell carcinoma (ESCC). Additionally, its safety and efficacy in ESCC patients after failure of first‐line programmed cell death protein‐1 (PD‐1) blockade plus chemotherapy have not been reported. In this study, we aimed to assess the efficacy and tolerability of nab‐paclitaxel regimens as second‐ or later‐line treatment in advanced ESCC. Methods We retrospectively reviewed clinical data of advanced ESCC patients who participated in a randomized phase III clinical study and received serplulimab or placebo plus chemotherapy at our institution, and consecutive patients who received subsequent nab‐paclitaxel‐based regimens as second‐ or later‐line treatment were included for data collection and analysis. Results A total of 39 patients were included, 25 (64.1%) received serplulimab plus chemotherapy and 14 (35.9%) received chemotherapy alone as first‐line treatment. Treatment strategies included nab‐paclitaxel monotherapy (7/39, 17.9%), or in combination with other chemotherapy (19/39, 48.7%), with anti‐PD‐1 antibodies (12/39, 30.8%) or with nimotuzumab (1/39, 2.6%). Overall, the objective response rate (ORR) and disease control rate (DCR) were 33.3% (13/39) and 61.5% (24/39), respectively. With a median follow‐up of 9.7 months, the median progression‐free survival and median overall survival were 5.0 and 7.9 months, respectively. The most common adverse events were neuropathy peripheral (30.8%), anemia (30.8%), neutrophil count decreased (23.1%), and nausea (20.5%). Conclusions Nab‐paclitaxel‐based regimen could be a safe and effective option as second‐ or later‐line treatment in patients with advanced ESCC, regardless of their previous exposure to PD‐1 inhibitors.https://doi.org/10.1111/1759-7714.14885chemotherapyesophageal squamous cell carcinomaimmunotherapynanoparticle albumin bound‐paclitaxel |
| spellingShingle | Dao Xin Yan Song Lan Mu Bo Zhang Ling Qi Jing Gao Xingyuan Wang Jianping Xu Tao Qu Jing Huang The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma Thoracic Cancer chemotherapy esophageal squamous cell carcinoma immunotherapy nanoparticle albumin bound‐paclitaxel |
| title | The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma |
| title_full | The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma |
| title_fullStr | The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma |
| title_full_unstemmed | The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma |
| title_short | The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma |
| title_sort | efficacy and safety of nanoparticle albumin bound paclitaxel based regimen as second or third line treatment in patients with advanced esophageal squamous cell carcinoma |
| topic | chemotherapy esophageal squamous cell carcinoma immunotherapy nanoparticle albumin bound‐paclitaxel |
| url | https://doi.org/10.1111/1759-7714.14885 |
| work_keys_str_mv | AT daoxin theefficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT yansong theefficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT lanmu theefficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT bozhang theefficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT lingqi theefficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT jinggao theefficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT xingyuanwang theefficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT jianpingxu theefficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT taoqu theefficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT jinghuang theefficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT daoxin efficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT yansong efficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT lanmu efficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT bozhang efficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT lingqi efficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT jinggao efficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT xingyuanwang efficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT jianpingxu efficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT taoqu efficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma AT jinghuang efficacyandsafetyofnanoparticlealbuminboundpaclitaxelbasedregimenassecondorthirdlinetreatmentinpatientswithadvancedesophagealsquamouscellcarcinoma |